Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 28 of 5804
-
New chikungunya vaccine trial aims to protect millions
⭐️ VACCINE ⭐️ Recruiting nowA Seamless Phase II/III, Observer-blind, Multi-centre, Randomized Clinical Trial to Evaluate Immunogenicity and Safety of BBV87, an Inactivated Chikungunya Virus Vaccine in Healthy Subjects 12-65 Years of Age
Phase: PHASE2, PHASE3 • Sponsor: Bharat Biotech International Limited • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:24 UTC
-
Magic mushroom compound could help treat anorexia in young adults
Disease control Recruiting nowThe goal of this clinical trial is to learn if psilocybin, given with psychological support, is safe and helps treat anorexia nervosa in young adults. Anorexia nervosa is a serious eating disorder that currently has no approved medicine. Psilocybin is a psychedelic substance that…
Phase: PHASE2 • Sponsor: Region Skane • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Nano-ink gel could replace repeated skull surgeries for kids with rare genetic disorders
Disease control Not yet recruitingSyndromic craniosynostoses (SCS) are rare genetic disorders defined by premature cranial suture fusion, resulting in abnormal craniofacial development and constrained brain growth. These conditions, including Muenke, Saethre-Chotzen, Crouzon, Apert, Pfeiffer and craniofrontonasal…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Double-Barreled attack: CAR-T plus stem cell transplant takes on aggressive lymphoma
Disease control Recruiting nowThis is a prospective, single-arm, single-center, open-label clinical study, aiming to evaluate the efficacy and safety of CAR-T combined with ASCT in the treatment of relapsed/refractory large B-cell lymphoma with high-risk factors.
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo aims to outsmart aggressive colon cancer
Disease control Recruiting nowThis is a randomized, open-label, controlled, multicenter phase 3 study. All patients are resectable microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer. The purpose of this study is to evaluate the efficacy and safety of neoadjuvant/adjuvant …
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for stomach cancer: targeted drug combo enters final testing
Disease control Recruiting nowThis study primarily evaluates the efficacy and safety of the LM-302 plus tislelizumab regimen versus tislelizumab plus chemotherapy in the treatment of previously untreated locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma patients w…
Phase: PHASE3 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for aggressive lung cancer: experimental drug combo enters final testing
Disease control Recruiting nowThis study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival when compared to standard treatment alone.…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Hope for Late-Stroke patients: clot removal may boost recovery even after 24 hours
Disease control Recruiting nowSELECT LATE trial aims to evaluate if addition of endovascular thrombectomy to medical management in patients presenting with acute ischemic stroke and a proximal large vessel occlusion in the anterior circulation between 24 and 72 hours of stroke onset results in achieving bette…
Phase: NA • Sponsor: Amrou Sarraj • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for pancreatic cancer: targeted pill plus chemotherapy in Late-Stage trial
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New pill combo aims to fight advanced kidney cancer
Disease control Recruiting nowResearchers are looking for new ways to treat advanced renal cell carcinoma (RCC). A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy. Targeted therapy is a treatment that works to control how specific types of …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Pfizer gives lyme vaccine a fifth dose — will it boost protection?
⭐️ VACCINE ⭐️ Recruiting nowThe purpose of this study is to learn about the safety effects of the Lyme disease vaccine (called VLA15), and its ability to protect people from Lyme disease after a 5th dose of the vaccine. This study is seeking participants who: * are generally healthy and 7 years of age and…
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:29 UTC
-
Could caffeine help save newborn brains? major trial launches
Disease control Recruiting nowCHIME is a randomized, parallel-arm, double-blind, placebo-controlled trial focused on infants with hypoxic ischemic encephalopathy (HIE). The trial will recruit neonates who are diagnosed with HIE within six hours after birth based on physiologic criteria (acidosis noted on an u…
Phase: PHASE3 • Sponsor: NICHD Global Network for Women's and Children's Health • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Gene therapy may free gaucher patients from lifelong infusions
Disease control Recruiting nowThis study is a Phase 3, non-randomized, multicenter, efficacy and safety study in adult patients with Gaucher disease Type 1, on stable treatment with enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) for at least 2 years. The study aims to confirm the effica…
Phase: PHASE3 • Sponsor: Spur Therapeutics • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Gene therapy breakthrough offers hope for Transfusion-Free life in thalassemia
Disease control Not yet recruitingThe goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 in treating patients with β-Thalassemia Major
Phase: PHASE2 • Sponsor: CorrectSequence Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Oxygen chambers could save lives from Flesh-Eating bacteria
Disease control Recruiting nowNecrotizing soft-tissue infection (NSTI) is a rare, severe, fast-progressing bacterial infection within the soft tissue compartment. The NSTI mortality rate remain high and largely unaltered in the last decades. The standard of care in NSTI is multidisciplinary and includes surge…
Phase: PHASE4 • Sponsor: Ole Hyldegaard • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New drug combo aims to extend remission in ovarian cancer
Disease control Recruiting nowThis Phase 3 study will be conducted in different countries around the world with up to about 544 participants. The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with available standard of care therapy that is already approved a…
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Gene therapy aims to restore hearing in deaf children
Disease control Recruiting nowThis study is a multicenter, single-arm, open-label Phase I/II clinical trial, which is designed to evaluate the safety, tolerability and efficacy of EHT102 injection in treating congenital hearing loss secondary to biallelic mutations of OTOF (DFNB9).Up to 30 pediatric participa…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Euhearing Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for deadly lymphoma combo: drug cocktail targets both cancer and immune chaos
Disease control Recruiting nowExtranodal NK/T-cell lymphoma (NKTCL) is an aggressive EBV-associated lymphoma with poor prognosis, highly prevalent in China. Early-stage NKTCL achieves favorable long-term survival, while advanced disease shows dismal outcomes with no standard therapy. Notably, 10%-20% of patie…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
HIV cure hope: three old drugs aim to flush out and destroy hidden virus
Disease control Not yet recruitingThe PLUTO trial aims to contribute to the worldwide search for a functional cure of HIV. One the strategies ("shock and kill' strategy) aims to reverse the HIV-reservoir from latency by increasing cell-associated HIV-RNA, which will lead to increased antigen presentation, trigger…
Phase: PHASE1, PHASE2 • Sponsor: Erasmus Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Psychedelic-Assisted therapy targets Gut-Brain link in trauma depression
Disease control Recruiting nowTrauma-related Major Depressive Disorder (MDD) is frequently associated with poor response to conventional antidepressants, persistent psychological distress, and alterations in gut-brain axis function. Existing assessment tools primarily diagnose depression or PTSD but provide l…
Phase: PHASE3 • Sponsor: Khyber Medical University Peshawar • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC